195 related articles for article (PubMed ID: 22931328)
1. Natalizumab-associated progressive multifocal leukoencephalopathy.
Cervera C
N Engl J Med; 2012 Aug; 367(9):871; author reply 872. PubMed ID: 22931328
[No Abstract] [Full Text] [Related]
2. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
Ropper AH
N Engl J Med; 2012 May; 366(20):1938-9. PubMed ID: 22591300
[No Abstract] [Full Text] [Related]
3. Natalizumab-associated progressive multifocal leukoencephalopathy.
Mancini N; Clementi M; Burioni R
N Engl J Med; 2012 Aug; 367(9):871-2; author reply 872. PubMed ID: 22931329
[No Abstract] [Full Text] [Related]
4. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
Warnke C; Adams O; Hartung HP; Gold R; Hemmer B; Hohlfeld R; Stangel M; Zipp F; Wiendl H; Kieseier BC
Nervenarzt; 2011 Oct; 82(10):1314-9. PubMed ID: 21656322
[No Abstract] [Full Text] [Related]
5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
8. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Tur C; Montalban X
Mult Scler; 2014 Apr; 20(4):510-1. PubMed ID: 24468818
[No Abstract] [Full Text] [Related]
9. Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort.
Zahednasab H
Neurology; 2012 Nov; 79(19):2010; author reply 2010-1. PubMed ID: 23128444
[No Abstract] [Full Text] [Related]
10. Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
O'Connor PW
Can J Neurol Sci; 2012 Sep; 39(5):670-5. PubMed ID: 22931715
[No Abstract] [Full Text] [Related]
11. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
12. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
Travasarou M; Marousi S; Papageorgiou E; Karageorgiou CE
Clin Neurol Neurosurg; 2013 Jun; 115(6):827-9. PubMed ID: 22920632
[No Abstract] [Full Text] [Related]
13. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
Hay M; Leguy S; Cahagne V; Lassalle N; Le Page E; Michel L
Rev Neurol (Paris); 2024 Jun; 180(6):565-567. PubMed ID: 38429158
[No Abstract] [Full Text] [Related]
14. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
Tur C; Tintoré M; Vidal-Jordana A; Castilló J; Galán I; Río J; Arrambide G; Comabella M; Arévalo MJ; Horno R; Vicente MJ; Caminero A; Nos C; Sastre-Garriga J; Montalban X
Mult Scler; 2012 Aug; 18(8):1193-6. PubMed ID: 22383232
[TBL] [Abstract][Full Text] [Related]
15. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
16. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.
Conway DS; Cohen JA
Mult Scler; 2014 Sep; 20(10):1280-1. PubMed ID: 25160120
[No Abstract] [Full Text] [Related]
19. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
Jeantin L; Shor N; Pallix-Guyot M; Roos-Weil D; Bellanger A; Le Garff-Tavernier M; Papeix C; Weiss N; Pourcher V
J Neurol; 2024 Feb; 271(2):729-732. PubMed ID: 37910249
[No Abstract] [Full Text] [Related]
20. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
